LUNG trades 95.3% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LUNG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Pulmonx Corporation (LUNG) has a Wall Street consensus price target of $5.00, based on estimates from 9 covering analysts. With the stock currently trading at $2.56, this represents a potential upside of +95.3%. The company has a market capitalization of $108M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, LUNG trades at a trailing P/E of -2.6x. Analysts expect EPS to grow +2.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INSPInspire Medical Systems, Inc. | $1.8B | $63.98 | $64.67 | +1.1% | Hold | 51.3x | 29 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 ATRCAtriCure, Inc. | $3.0B | $58.54 | $60.17 | +2.8% | Buy | 541.5x | 20 |
 PRCTPROCEPT BioRobotics Corporation | $1.2B | $20.62 | $23.00 | +11.5% | Buy | — | 17 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.23 | $107.33 | +23.0% | Buy | 20.0x | 15 |
 ANGOAngioDynamics, Inc. | $485M | $11.73 | $19.00 | +62.0% | Hold | — | 11 |
 TMDXTransMedics Group, Inc. | $3.0B | $88.24 | $100.43 | +13.8% | Buy | 60.2x | 13 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
Quick answers to the most common questions about buying LUNG stock.
The consensus Wall Street price target for LUNG is $5, representing 95.3% upside from the current price of $2.56. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LUNG has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $5 implies 95.3% upside from current levels.
LUNG's current price is $2.56 with a consensus target of $5 (95.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for LUNG, while the most conservative target is $5. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
LUNG is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LUNG stock forecast based on 9 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LUNG, with a "Buy" consensus rating and $5 price target (95.3% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LUNG analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.